FibroBiologics announces expansion of wound care platform

FibroBiologics (FBLG) announced the expansion of its wound care platform into the treatment of patients with acute and chronic burn injuries. Building on its investigational fibroblast spheroid-based programs in chronic wound healing, FibroBiologics is applying the same core technology to address the significant unmet medical needs in burn care. In preclinical burn models, treatment with proprietary fibroblast spheroids was associated with nearly a four-fold increase in tissue-level IL-10, a cytokine known to support tissue repair and wound healing in skin. Additionally, CYWC628 drove a significant reduction in IL-1B, a key driver of inflammation in burn wounds, further supporting the potential of the platform to promote better, faster healing in patients with severe burns. “These new burn data reinforce our conviction that fibroblast spheroids can reshape how serious wounds are treated,” said Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics. “By combining strong signals of tissue repair with meaningful reductions in inflammatory markers, CYWC628 positions us to address a large, underserved market in burn care and create significant benefit for patients. We believe that a targeted, cell-based approach has the potential to improve healing outcomes, reduce complications, and ultimately change the standard of care for burn patients worldwide.”